{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T04:17:43Z","timestamp":1793852263077,"version":"4.6.1"},"reference-count":110,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["GR 1301\/22\\u20101"],"award-info":[{"award-number":["GR 1301\/22\\u20101"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["HX23OET9ZE"],"award-info":[{"award-number":["HX23OET9ZE"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Peptides"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.peptides.2022.170815","type":"journal-article","created":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T22:37:49Z","timestamp":1652999869000},"page":"170815","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"special_numbering":"C","title":["Involvement of complement peptides C3a and C5a in osteoarthritis pathology"],"prefix":"10.1016","volume":"154","author":[{"given":"Nicole","family":"Sch\u00e4fer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Gr\u00e4ssel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10182","key":"10.1016\/j.peptides.2022.170815_bib1","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1016\/S0140-6736(19)30417-9","article-title":"Osteoarthritis","volume":"393","author":"Hunter","year":"2019","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.peptides.2022.170815_bib2","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1002\/art.34453","article-title":"Osteoarthritis: a disease of the joint as an organ","volume":"64","author":"Loeser","year":"2012","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.peptides.2022.170815_bib3","article-title":"Osteoarthritis","volume":"2","author":"Martel-Pelletier","year":"2016","journal-title":"Nat. Rev. Dis. Prim."},{"issue":"11","key":"10.1016\/j.peptides.2022.170815_bib4","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1038\/nrrheum.2016.148","article-title":"Changes in the osteochondral unit during osteoarthritis: structure, function and cartilage-bone crosstalk","volume":"12","author":"Goldring","year":"2016","journal-title":"Nat. Rev. Rheumatol."},{"issue":"5","key":"10.1016\/j.peptides.2022.170815_bib5","first-page":"64","article-title":"Phenotypes of osteoarthritis: current state and future implications","volume":"37","author":"Deveza","year":"2019","journal-title":"Clin. Exp. Rheumatol."},{"issue":"5","key":"10.1016\/j.peptides.2022.170815_bib6","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.joca.2010.01.007","article-title":"Identifying different osteoarthritis phenotypes through epidemiology","volume":"18","author":"Felson","year":"2010","journal-title":"Osteoarthr. Cartil."},{"issue":"10","key":"10.1016\/j.peptides.2022.170815_bib7","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/nrrheum.2016.136","article-title":"Low-grade inflammation as a key mediator of the pathogenesis of osteoarthritis","volume":"12","author":"Robinson","year":"2016","journal-title":"Nat. Rev. Rheumatol."},{"issue":"1","key":"10.1016\/j.peptides.2022.170815_bib8","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-020-02410-w","article-title":"Proinflammatory T cell polarization is already present in patients with early knee osteoarthritis","volume":"23","author":"Rosshirt","year":"2021","journal-title":"Arthritis Res. Ther."},{"issue":"3","key":"10.1016\/j.peptides.2022.170815_bib9","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.clim.2012.12.011","article-title":"Immunopathogenesis of osteoarthritis","volume":"146","author":"Haseeb","year":"2013","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.peptides.2022.170815_bib10","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.22115.1","article-title":"Recent advances in the treatment of osteoarthritis","volume":"9","author":"Gr\u00e4ssel","year":"2020","journal-title":"F1000Research"},{"issue":"1","key":"10.1016\/j.peptides.2022.170815_bib11","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.joca.2012.11.012","article-title":"Osteoarthritis as an inflammatory disease (osteoarthritis is not osteoarthrosis!)","volume":"21","author":"Berenbaum","year":"2013","journal-title":"Osteoarthr. Cartil."},{"issue":"4","key":"10.1016\/j.peptides.2022.170815_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms22041996","article-title":"An evidence-based systematic review of human knee post-traumatic osteoarthritis (PTOA): timeline of clinical presentation and disease markers, comparison of knee joint PTOA models and early disease implications","volume":"22","author":"Khella","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.peptides.2022.170815_bib13","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21051560","article-title":"Pathomechanisms of posttraumatic osteoarthritis: chondrocyte behavior and fate in a precarious environment","volume":"21","author":"Riegger","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.peptides.2022.170815_bib14","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.joca.2005.01.005","article-title":"Synovitis: a potential predictive factor of structural progression of medial tibiofemoral knee osteoarthritis -- results of a 1 year longitudinal arthroscopic study in 422 patients","volume":"13","author":"Ayral","year":"2005","journal-title":"Osteoarthr. Cartil."},{"issue":"11","key":"10.1016\/j.peptides.2022.170815_bib15","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/nrrheum.2016.162","article-title":"The danger from within: alarmins in arthritis","volume":"12","author":"Nefla","year":"2016","journal-title":"Nat. Rev. Rheumatol."},{"issue":"4","key":"10.1016\/j.peptides.2022.170815_bib16","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1177\/1947603513495889","article-title":"The roles of mechanical stresses in the pathogenesis of osteoarthritis: implications for treatment of joint injuries","volume":"4","author":"Buckwalter","year":"2013","journal-title":"Cartilage"},{"issue":"5844","key":"10.1016\/j.peptides.2022.170815_bib17","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1126\/science.1144706","article-title":"A common fold mediates vertebrate defense and bacterial attack","volume":"317","author":"Rosado","year":"2007","journal-title":"Science"},{"issue":"6082","key":"10.1016\/j.peptides.2022.170815_bib18","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1038\/322831a0","article-title":"Structural\/functional similarity between proteins involved in complement- and cytotoxic T-lymphocyte-mediated cytolysis","volume":"322","author":"Tschopp","year":"1986","journal-title":"Nature"},{"key":"10.1016\/j.peptides.2022.170815_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.molimm.2017.05.012","article-title":"Intracellular complement \u2212 the complosome \u2212 in immune cell regulation","author":"Arbore","year":"2017","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.peptides.2022.170815_bib20","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.629986","article-title":"Complement has brains-do intracellular complement and immunometabolism cooperate in tissue homeostasis and behavior?","volume":"12","author":"Kunz","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.peptides.2022.170815_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.769242","article-title":"Complement factor H-related 3 enhanced inflammation and complement activation in human RPE cells","volume":"12","author":"Sch\u00e4fer","year":"2021","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.peptides.2022.170815_bib22","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/imr.12852","article-title":"Complement and human T cell metabolism: location, location, location","volume":"295","author":"West","year":"2020","journal-title":"Immunol. Rev."},{"issue":"3","key":"10.1016\/j.peptides.2022.170815_bib23","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1172\/JCI89412","article-title":"A C3(H20) recycling pathway is a component of the intracellular complement system","volume":"127","author":"Elvington","year":"2017","journal-title":"J. Clin. Investig."},{"issue":"5","key":"10.1016\/j.peptides.2022.170815_bib24","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/j.immuni.2021.03.003","article-title":"The complement system drives local inflammatory tissue priming by metabolic reprogramming of synovial fibroblasts","volume":"54","author":"Fri\u0161\u010di\u0107","year":"2021","journal-title":"Immunity"},{"issue":"5","key":"10.1016\/j.peptides.2022.170815_bib25","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1080\/15548627.2019.1580515","article-title":"Intracellular cytosolic complement component C3 regulates cytoprotective autophagy in pancreatic beta cells by interaction with ATG16L1","volume":"15","author":"King","year":"2019","journal-title":"Autophagy"},{"issue":"9","key":"10.1016\/j.peptides.2022.170815_bib26","doi-asserted-by":"crossref","first-page":"793","DOI":"10.3390\/antiox9090793","article-title":"Properdin modulates complement component production in stressed human primary retinal pigment epithelium cells","volume":"9","author":"Sch\u00e4fer","year":"2020","journal-title":"Antioxidants"},{"issue":"12","key":"10.1016\/j.peptides.2022.170815_bib27","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1038\/nm.2543","article-title":"Identification of a central role for complement in osteoarthritis","volume":"17","author":"Wang","year":"2011","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.peptides.2022.170815_bib28","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/s13075-016-1123-x","article-title":"The complement system is activated in synovial fluid from subjects with knee injury and from patients with osteoarthritis","volume":"18","author":"Struglics","year":"2016","journal-title":"Arthritis Res. Ther."},{"issue":"5","key":"10.1016\/j.peptides.2022.170815_bib29","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.joca.2020.01.004","article-title":"Crucial role of the terminal complement complex in chondrocyte death and hypertrophy after cartilage trauma","volume":"28","author":"Riegger","year":"2020","journal-title":"Osteoarthr. Cartil."},{"issue":"7","key":"10.1016\/j.peptides.2022.170815_bib30","first-page":"781","article-title":"Impact of the complement cascade on posttraumatic cartilage inflammation and degradation","volume":"22","author":"Jonh","year":"2007","journal-title":"Histol. Histopathol."},{"issue":"4","key":"10.1016\/j.peptides.2022.170815_bib31","first-page":"648","article-title":"Synthesis of classical pathway complement components by chondrocytes","volume":"88","author":"Bradley","year":"1996","journal-title":"Immunology"},{"issue":"5","key":"10.1016\/j.peptides.2022.170815_bib32","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/j.1365-2613.2009.00676.x","article-title":"Analysing the role of endogenous matrix molecules in the development of osteoarthritis","volume":"90","author":"Sofat","year":"2009","journal-title":"Int. J. Exp. Pathol."},{"issue":"2","key":"10.1016\/j.peptides.2022.170815_bib33","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20020447","article-title":"The expression of thrombospondin-4 correlates with disease severity in osteoarthritic knee cartilage","author":"Maly","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.peptides.2022.170815_bib34","doi-asserted-by":"crossref","DOI":"10.1177\/1179544117751430","article-title":"Osteoarthritis and the complement cascade","volume":"11","author":"Silawal","year":"2018","journal-title":"Clin. Med. Insights Arthritis Musculoskelet. Disord."},{"issue":"October","key":"10.1016\/j.peptides.2022.170815_bib35","first-page":"1","article-title":"Complement expression and activation in osteoarthritis joint compartments","volume":"11","author":"Assirelli","year":"2020","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.peptides.2022.170815_bib36","first-page":"304","article-title":"Effect of exercise on complement activity","volume":"65","author":"Smith","year":"1990","journal-title":"Ann. Allergy"},{"issue":"1","key":"10.1016\/j.peptides.2022.170815_bib37","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1055\/s-2007-1021016","article-title":"Anaphylatoxin C5a production during short-term submaximal dynamic exercise in man","volume":"v15","author":"Camus","year":"1994","journal-title":"Int. J. Sport. Med."},{"issue":"3","key":"10.1016\/j.peptides.2022.170815_bib38","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/art.38290","article-title":"Impact of exercise type and dose on pain and disability in knee osteoarthritis: a systematic review and meta-regression analysis of randomized controlled trials","volume":"vol. 66","author":"Juhl","year":"2014","journal-title":"Arthritis Rheumatol."},{"issue":"6","key":"10.1016\/j.peptides.2022.170815_bib39","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1136\/annrheumdis-2018-214627","article-title":"Running promotes chronicity of arthritis by local modulation of complement activators and impairing T regulatory feedback loops","volume":"78","author":"Cambr\u00e9","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.peptides.2022.170815_bib40","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/978-3-319-75402-4_6","article-title":"Anaphylatoxin signaling in retinal pigment and choroidal endothelial cells: characteristics and relevance to age-related macular degeneration","volume":"1074","author":"Rohrer","year":"2018","journal-title":"Adv. Exp. Med. Biol."},{"issue":"1\u20132","key":"10.1016\/j.peptides.2022.170815_bib41","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.vetimm.2005.07.009","article-title":"Evolution of anaphylatoxins, their diversity and novel roles in innate immunity: insights from the study of fish complement","volume":"108","author":"Sunyer","year":"2005","journal-title":"Vet. Immunol. Immunopathol."},{"issue":"14","key":"10.1016\/j.peptides.2022.170815_bib42","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1016\/j.molimm.2009.04.027","article-title":"The role of the anaphylatoxins in health and disease","volume":"46","author":"Klos","year":"2009","journal-title":"Mol. Immunol."},{"issue":"3","key":"10.1016\/j.peptides.2022.170815_bib43","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1042\/bj2350723","article-title":"The C3 convertase of the alternative pathway of human complement. Enzymic properties of the bimolecular proteinase","volume":"235","author":"Pangburn","year":"1986","journal-title":"Biochem. J."},{"issue":"4","key":"10.1016\/j.peptides.2022.170815_bib44","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.4049\/jimmunol.166.4.2635","article-title":"Formation of high-affinity C5 convertases of the alternative pathway of complement","volume":"166","author":"Rawal","year":"2001","journal-title":"J. Immunol."},{"issue":"11","key":"10.1016\/j.peptides.2022.170815_bib45","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.molimm.2003.10.002","article-title":"Carboxypeptidase N: a pleiotropic regulator of inflammation","volume":"40","author":"Matthews","year":"2004","journal-title":"Mol. Immunol."},{"issue":"12","key":"10.1016\/j.peptides.2022.170815_bib46","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1172\/JCI106462","article-title":"Anaphylatoxin inactivator of human plasma: its isolation and characterization as a carboxypeptidase","volume":"49","author":"Bokisch","year":"1970","journal-title":"J. Clin. Investig."},{"issue":"8","key":"10.1016\/j.peptides.2022.170815_bib47","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1111\/jth.14199","article-title":"Carboxypeptidase B2 and carboxypeptidase N in the crosstalk between coagulation, thrombosis, inflammation, and innate immunity","volume":"16","author":"Leung","year":"2018","journal-title":"J. Thromb. Haemost."},{"issue":"8","key":"10.1016\/j.peptides.2022.170815_bib48","doi-asserted-by":"crossref","first-page":"3542","DOI":"10.4049\/jimmunol.1403068","article-title":"Is the complement activation product C3a a proinflammatory molecule? Re-evaluating the evidence and the myth","volume":"194","author":"Coulthard","year":"2015","journal-title":"J. Immunol."},{"issue":"52","key":"10.1016\/j.peptides.2022.170815_bib49","doi-asserted-by":"crossref","first-page":"31189","DOI":"10.1074\/jbc.M115.671180","article-title":"Complement component C5a primes retinal pigment epithelial cells for inflammasome activation by lipofuscin-mediated photooxidative damage","volume":"290","author":"Brandstetter","year":"2015","journal-title":"J. Biol. Chem."},{"issue":"June","key":"10.1016\/j.peptides.2022.170815_bib50","article-title":"Anaphylatoxins activate Ca2+, Akt\/PI3-Kinase, and FOXO1\/FoxP3 in the retinal pigment epithelium","volume":"8","author":"Busch","year":"2017","journal-title":"Front. Immunol."},{"issue":"Oct","key":"10.1016\/j.peptides.2022.170815_bib51","article-title":"Asparaginyl Endopeptidase (Legumain) supports human Th1 induction via cathepsin L-mediated intracellular C3 activation","volume":"9","author":"Freeley","year":"2018","journal-title":"Front. Immunol."},{"issue":"1\u20132","key":"10.1016\/j.peptides.2022.170815_bib52","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.molimm.2011.12.005","article-title":"Cathepsin D is released after severe tissue trauma in vivo and is capable of generating C5a in vitro","volume":"50","author":"Huber-Lang","year":"2012","journal-title":"Mol. Immunol."},{"issue":"6","key":"10.1016\/j.peptides.2022.170815_bib53","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.immuni.2013.10.018","article-title":"Intracellular complement activation sustains T cell homeostasis and mediates effector differentiation","volume":"39","author":"Liszewski","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.peptides.2022.170815_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.molimm.2017.05.019","article-title":"Novel insights into the expression pattern of anaphylatoxin receptors in mice and men","author":"Laumonnier","year":"2017","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.peptides.2022.170815_bib55","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1146\/annurev.immunol.23.021704.115835","article-title":"Role of C5a in inflammatory responses","volume":"23","author":"Guo","year":"2005","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.peptides.2022.170815_bib56","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.molimm.2017.05.015","article-title":"New concepts on the therapeutic control of complement anaphylatoxin receptors","volume":"89","author":"Hawksworth","year":"2017","journal-title":"Mol. Immunol."},{"issue":"1\u20132","key":"10.1016\/j.peptides.2022.170815_bib57","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0169-328X(00)00242-4","article-title":"Identification of four novel human G protein-coupled receptors expressed in the brain","volume":"86","author":"Lee","year":"2001","journal-title":"Brain Res. Mol. Brain Res."},{"issue":"12","key":"10.1016\/j.peptides.2022.170815_bib58","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.4049\/jimmunol.1900371","article-title":"The complement receptor C5aR2: a powerful modulator of innate and adaptive immunity","volume":"202","author":"Li","year":"2019","journal-title":"J. Immunol."},{"issue":"3","key":"10.1016\/j.peptides.2022.170815_bib59","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1096\/fj.12-220509","article-title":"C5L2: a controversial receptor of complement anaphylatoxin, C5a","volume":"27","author":"Li","year":"2013","journal-title":"FASEB J."},{"issue":"1","key":"10.1016\/j.peptides.2022.170815_bib60","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1124\/pr.111.005223","article-title":"International union of basic and clinical pharmacology. [corrected]. LXXXVII. Complement peptide C5a, C4a, and C3a receptors","volume":"65","author":"Klos","year":"2013","journal-title":"Pharmacol. Rev."},{"issue":"13","key":"10.1016\/j.peptides.2022.170815_bib61","doi-asserted-by":"crossref","first-page":"11123","DOI":"10.1074\/jbc.M206169200","article-title":"The chemoattractant receptor-like protein C5L2 binds the C3a des-Arg77\/acylation-stimulating protein","volume":"278","author":"Kalant","year":"2003","journal-title":"J. Biol. Chem."},{"issue":"51","key":"10.1016\/j.peptides.2022.170815_bib62","doi-asserted-by":"crossref","first-page":"39088","DOI":"10.1074\/jbc.M609734200","article-title":"Ligand specificity of the anaphylatoxin C5L2 receptor and its regulation on myeloid and epithelial cell lines","volume":"281","author":"Johswich","year":"2006","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.peptides.2022.170815_bib63","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1084\/jem.186.2.199","article-title":"The human C3a receptor is expressed on neutrophils and monocytes, but not on B or T lymphocytes","volume":"186","author":"Martin","year":"1997","journal-title":"J. Exp. Med."},{"issue":"20","key":"10.1016\/j.peptides.2022.170815_bib64","doi-asserted-by":"crossref","first-page":"3473","DOI":"10.1182\/blood-2013-05-502229","article-title":"C3a modulates IL-1\u03b2 secretion in human monocytes by regulating ATP efflux and subsequent NLRP3 inflammasome activation","volume":"122","author":"Asgari","year":"2013","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.peptides.2022.170815_bib65","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.4049\/jimmunol.157.4.1693","article-title":"C3a and C5a are chemotaxins for human mast cells and act through distinct receptors via a pertussis toxin-sensitive signal transduction pathway","volume":"157","author":"Nilsson","year":"1996","journal-title":"J. Immunol."},{"issue":"4","key":"10.1016\/j.peptides.2022.170815_bib66","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.4049\/jimmunol.169.4.2102","article-title":"Complement c3a and c5a induce different signal transduction cascades in endothelial cells","volume":"169","author":"Schraufstatter","year":"2002","journal-title":"J. Immunol."},{"issue":"42","key":"10.1016\/j.peptides.2022.170815_bib67","doi-asserted-by":"crossref","first-page":"43487","DOI":"10.1074\/jbc.M404124200","article-title":"Characterization of C3a and C5a receptors in rat cerebellar granule neurons during maturation. Neuroprotective effect of C5a against apoptotic cell death","volume":"279","author":"B\u00e9nard","year":"2004","journal-title":"J. Biol. Chem."},{"issue":"10","key":"10.1016\/j.peptides.2022.170815_bib68","doi-asserted-by":"crossref","first-page":"5086","DOI":"10.4049\/jimmunol.1102914","article-title":"Complement activation product C5a is a selective suppressor of TLR4-induced, but not TLR3-induced, production of IL-27(p28) from macrophages","volume":"188","author":"Bosmann","year":"2012","journal-title":"J. Immunol."},{"issue":"3","key":"10.1016\/j.peptides.2022.170815_bib69","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.4049\/jimmunol.166.3.2025","article-title":"Expression of the complement anaphylatoxin C3a and C5a receptors on bronchial epithelial and smooth muscle cells in models of sepsis and asthma","volume":"166","author":"Drouin","year":"2001","journal-title":"J. Immunol."},{"issue":"9","key":"10.1016\/j.peptides.2022.170815_bib70","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.98254","article-title":"Complement receptor C3aR1 controls neutrophil mobilization following spinal cord injury through physiological antagonism of CXCR2","volume":"4","author":"Brennan","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.peptides.2022.170815_bib71","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1146\/annurev.iy.12.040194.004015","article-title":"C5A anaphylatoxin and its seven transmembrane-segment receptor","volume":"12","author":"Gerard","year":"1994","journal-title":"Annu. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.peptides.2022.170815_bib72","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/imr.12473","article-title":"Old dogs-new tricks: immunoregulatory properties of C3 and C5 cleavage fragments","volume":"274","author":"Verschoor","year":"2016","journal-title":"Immunol. Rev."},{"issue":"2","key":"10.1016\/j.peptides.2022.170815_bib73","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.immuni.2016.08.003","article-title":"Complement-mediated regulation of metabolism and basic cellular processes","volume":"45","author":"Hess","year":"2016","journal-title":"Immunity"},{"issue":"7","key":"10.1016\/j.peptides.2022.170815_bib74","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/icb.2014.32","article-title":"C5a2 can modulate ERK1\/2 signaling in macrophages via heteromer formation with C5a1 and \u03b2-arrestin recruitment","volume":"92","author":"Croker","year":"2014","journal-title":"Immunol. Cell Biol."},{"issue":"6","key":"10.1016\/j.peptides.2022.170815_bib75","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1074\/jbc.M609178200","article-title":"The role of the N-terminal domain of the complement fragment receptor C5L2 in ligand binding","volume":"282","author":"Scola","year":"2007","journal-title":"J. Biol. Chem."},{"issue":"31","key":"10.1016\/j.peptides.2022.170815_bib76","doi-asserted-by":"crossref","first-page":"9406","DOI":"10.1021\/bi034489v","article-title":"C5L2, a nonsignaling C5A binding protein","volume":"42","author":"Okinaga","year":"2003","journal-title":"Biochemistry"},{"issue":"4","key":"10.1016\/j.peptides.2022.170815_bib77","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.cellsig.2012.12.010","article-title":"C5L2 and C5aR interaction in adipocytes and macrophages: insights into adipoimmunology","volume":"25","author":"Poursharifi","year":"2013","journal-title":"Cell Signal."},{"issue":"10","key":"10.1016\/j.peptides.2022.170815_bib78","doi-asserted-by":"crossref","first-page":"7633","DOI":"10.1074\/jbc.M109.092106","article-title":"The C5a receptor (C5aR) C5L2 is a modulator of C5aR-mediated signal transduction","volume":"285","author":"Bamberg","year":"2010","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.peptides.2022.170815_bib79","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s00441-012-1497-2","article-title":"Anaphylatoxin receptors and complement regulatory proteins in human articular and non-articular chondrocytes: interrelation with cytokines","volume":"350","author":"Schulze-Tanzil","year":"2012","journal-title":"Cell Tissue Res."},{"issue":"2","key":"10.1016\/j.peptides.2022.170815_bib80","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s00296-002-0199-6","article-title":"Expression of the anaphylatoxin receptor C5aR (CD88) by human articular chondrocytes","volume":"22","author":"Onuma","year":"2002","journal-title":"Rheumatol. Int."},{"issue":"9","key":"10.1016\/j.peptides.2022.170815_bib81","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1002\/jcb.23186","article-title":"Complement C3a and C5a modulate osteoclast formation and inflammatory response of osteoblasts in synergism with IL-1\u03b2","volume":"112","author":"Ignatius","year":"2011","journal-title":"J. Cell. Biochem."},{"issue":"12","key":"10.1016\/j.peptides.2022.170815_bib82","doi-asserted-by":"crossref","first-page":"6002","DOI":"10.1111\/jcmm.13873","article-title":"C5aR1 interacts with TLR2 in osteoblasts and stimulates the osteoclast-inducing chemokine CXCL10","volume":"22","author":"M\u00f6dinger","year":"2018","journal-title":"J. Cell. Mol. Med."},{"issue":"6","key":"10.1016\/j.peptides.2022.170815_bib83","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0179512","article-title":"Osteoblast-specific overexpression of complement receptor C5aR1 impairs fracture healing","volume":"12","author":"Bergdolt","year":"2017","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.peptides.2022.170815_bib84","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1002\/jbmr.2187","article-title":"Osteoclast-derived complement component 3a stimulates osteoblast differentiation","volume":"29","author":"Matsuoka","year":"2014","journal-title":"J. Bone Miner. Res."},{"issue":"10","key":"10.1016\/j.peptides.2022.170815_bib85","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1016\/j.joca.2016.05.014","article-title":"Bone morphogenetic protein 2\/SMAD signalling in human ligamentocytes of degenerated and aged anterior cruciate ligaments","volume":"24","author":"Ruschke","year":"2016","journal-title":"Osteoarthr. Cartil."},{"issue":"4","key":"10.1016\/j.peptides.2022.170815_bib86","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.molimm.2012.09.001","article-title":"Complement gene expression is regulated by pro-inflammatory cytokines and the anaphylatoxin C3a in human tenocytes","volume":"53","author":"Busch","year":"2013","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.peptides.2022.170815_bib87","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.phrs.2016.02.004","article-title":"C5a and pain development: an old molecule, a new target","volume":"112","author":"Quadros","year":"2016","journal-title":"Pharmacol. Res."},{"issue":"2","key":"10.1016\/j.peptides.2022.170815_bib88","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.pain.2009.11.021","article-title":"Nociceptive sensitization by complement C5a and C3a in mouse","volume":"148","author":"Jang","year":"2010","journal-title":"Pain"},{"issue":"5","key":"10.1016\/j.peptides.2022.170815_bib89","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1097\/BOR.0b013e3283103d12","article-title":"Angiogenesis in osteoarthritis","volume":"20","author":"Ashraf","year":"2008","journal-title":"Curr. Opin. Rheumatol."},{"issue":"1","key":"10.1016\/j.peptides.2022.170815_bib90","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-015-0586-5","article-title":"Detecting cathepsin activity in human osteoarthritis via activity-based probes","volume":"17","author":"Ben-Aderet","year":"2015","journal-title":"Arthritis Res. Ther."},{"issue":"1","key":"10.1016\/j.peptides.2022.170815_bib91","doi-asserted-by":"crossref","first-page":"99","DOI":"10.18388\/abp.2013_1957","article-title":"The activity of cathepsin D and alpha-1 antitrypsin in hip and knee osteoarthritis","volume":"60","author":"Olszewska-Slonina","year":"2013","journal-title":"Acta Biochim. Pol."},{"issue":"8","key":"10.1016\/j.peptides.2022.170815_bib92","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.4252\/wjsc.v7.i8.1090","article-title":"Complement activation in the context of stem cells and tissue repair","volume":"7","author":"IU","year":"2015","journal-title":"World J. Stem Cells"},{"issue":"6","key":"10.1016\/j.peptides.2022.170815_bib93","doi-asserted-by":"crossref","first-page":"3827","DOI":"10.4049\/jimmunol.0803055","article-title":"C3a and C5a are chemotactic factors for human mesenchymal stem cells, which cause prolonged ERK1\/2 phosphorylation","volume":"182","author":"Schraufstatter","year":"2009","journal-title":"J. Immunol."},{"issue":"12","key":"10.1016\/j.peptides.2022.170815_bib94","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/nrd4657","article-title":"Complement, a target for therapy in inflammatory and degenerative diseases","volume":"14","author":"Morgan","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.peptides.2022.170815_bib95","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.molimm.2018.06.005","article-title":"Tissue-targeted complement therapeutics","volume":"102","author":"Tomlinson","year":"2018","journal-title":"Mol. Immunol."},{"issue":"16","key":"10.1016\/j.peptides.2022.170815_bib96","doi-asserted-by":"crossref","first-page":"4080","DOI":"10.1016\/j.molimm.2008.07.010","article-title":"Regulation of tissue inflammation by thrombin-activatable carboxypeptidase B (or TAFI)","volume":"45","author":"Leung","year":"2008","journal-title":"Mol. Immunol."},{"issue":"9","key":"10.1016\/j.peptides.2022.170815_bib97","first-page":"3517","article-title":"Plasma carboxypeptidase B downregulates inflammatory responses in autoimmune arthritis","volume":"121","author":"Song","year":"2011","journal-title":"J. Clin. Investig."},{"issue":"1","key":"10.1016\/j.peptides.2022.170815_bib98","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/art.38213","article-title":"Brief report: carboxypeptidase B serves as a protective mediator in osteoarthritis","volume":"66","author":"Lepus","year":"2014","journal-title":"Arthritis Rheumatol."},{"issue":"10","key":"10.1016\/j.peptides.2022.170815_bib99","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0164646","article-title":"Characterization of pharmacologic and pharmacokinetic properties of CCX168, a potent and selective orally administered complement 5a receptor inhibitor, based on preclinical evaluation and randomized phase 1 clinical study","volume":"11","author":"Bekker","year":"2016","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.peptides.2022.170815_bib100","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s40265-021-01643-6","article-title":"Avacopan: first approval","volume":"82","author":"Lee","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.peptides.2022.170815_bib101","first-page":"273","article-title":"\u201cCompstatin: a complement inhibitor on its way to clinical application,\u201d","volume":"vol. 632","author":"Ricklin","year":"2008","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.peptides.2022.170815_bib102","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2021.108785","article-title":"\u201cFrom discovery to approval: A brief history of the compstatin family of complement C3 inhibitors,\u201d","volume":"vol. 235","author":"Mastellos","year":"2022","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.peptides.2022.170815_bib103","article-title":"\u201cComplement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration,\u201d","author":"Liao","year":"2019","journal-title":"Ophthalmology"},{"issue":"8","key":"10.1016\/j.peptides.2022.170815_bib104","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.tibs.2020.04.004","article-title":"\u201cEmerging Insights into the Structure and Function of Complement C5a Receptors,\u201d","volume":"vol. 45","author":"Pandey","year":"2020","journal-title":"Trends Biochem. Sci."},{"issue":"9","key":"10.1016\/j.peptides.2022.170815_bib105","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1096\/fj.05-5814com","article-title":"Therapeutic activity of C5a receptor antagonists in a rat model of neurodegeneration","volume":"20","author":"Woodruff","year":"2006","journal-title":"FASEB J."},{"issue":"12","key":"10.1016\/j.peptides.2022.170815_bib106","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1093\/rheumatology\/kem222","article-title":"Blocking the receptor for C5a in patients with rheumatoid arthritis does not reduce synovial inflammation","volume":"46","author":"Vergunst","year":"2007","journal-title":"Rheumatology"},{"issue":"5","key":"10.1016\/j.peptides.2022.170815_bib107","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1021\/acsomega.9b03735","article-title":"Preclinical pharmacokinetics of complement C5a receptor antagonists PMX53 and PMX205 in mice","volume":"5","author":"Kumar","year":"2020","journal-title":"ACS Omega"},{"issue":"12","key":"10.1016\/j.peptides.2022.170815_bib108","doi-asserted-by":"crossref","first-page":"e764","DOI":"10.1016\/S2665-9913(20)30341-6","article-title":"Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial","volume":"2","author":"Vlaar","year":"2020","journal-title":"Lancet Rheumatol."},{"key":"10.1016\/j.peptides.2022.170815_bib109","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.smim.2018.01.001","article-title":"Complement involvement in bone homeostasis and bone disorders","volume":"37","author":"M\u00f6dinger","year":"2018","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.peptides.2022.170815_bib110","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.109764","article-title":"Inhibition of osteoclast activity by complement regulation with DF3016A, a novel small-molecular-weight C5aR inhibitor","volume":"123","author":"D\u2019Angelo","year":"2020","journal-title":"Biomed. Pharmacother."}],"container-title":["Peptides"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019697812200081X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019697812200081X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T05:40:30Z","timestamp":1777527630000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S019697812200081X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":110,"alternative-id":["S019697812200081X"],"URL":"https:\/\/doi.org\/10.1016\/j.peptides.2022.170815","relation":{},"ISSN":["0196-9781"],"issn-type":[{"value":"0196-9781","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Involvement of complement peptides C3a and C5a in osteoarthritis pathology","name":"articletitle","label":"Article Title"},{"value":"Peptides","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.peptides.2022.170815","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"170815"}}